Most of the small compounds used in AD therapy are focused toward important enzymes and pathways that are intricate in the processing of tau or Aβ proteins, including γ-secretase inhibitors such as tarenflurbil, avagacestat, and semagacestat, and β-secretase inhibitors such as lanabecestat, verubecestat, and atabecestat. The gene discussed is MAPT; the disease is Alzheimer disease.